目的:观察自体骨髓单个核细胞冠脉内移植治疗扩张型心肌病的临床疗效。方法:扩张型心肌病16例(男性5例, 女性11例),平均年龄(45．3±10．8)岁,心功能Ⅳ级,左室射血分数(LVEF)<30％。抽取骨髓,用Ficoll密度梯度离心法分离骨髓单...目的:观察自体骨髓单个核细胞冠脉内移植治疗扩张型心肌病的临床疗效。方法:扩张型心肌病16例(男性5例, 女性11例),平均年龄(45．3±10．8)岁,心功能Ⅳ级,左室射血分数(LVEF)<30％。抽取骨髓,用Ficoll密度梯度离心法分离骨髓单个核细胞,经外周动脉穿刺插管,将骨髓单个核细胞分别直接注入左、右冠脉。比较移植前后心功能的变化。结果:移植3个月后,心功能(NYHA分级)得到改善,总有效率87．5％,超声心动图检查均示左室舒张末径(mm)(72．94± 4．01 vs 63．63±2．58．P<0．001)、左室收缩末径(mm)(52．00±2．80 vs 44．38±1．78．P<0．001)减小,左室射血分数(％) (22．88±5．29vs33．81±3．33,P<0．001)、短轴缩短率(％)(12．00±2．39 vs 20．94±3．70,P<0．001)明显增加;心脏ECT 检查与术前相比,术后患者缺血及坏死心肌节段减少,(3．4±0．3vs2．1±0．4,P<0．05)(2．5±0．5 vs 1．6±0.3,P< 0．01)个。结论:自体骨髓单个核细胞移植有可能通过缺血心肌血运改善,坏死心肌区有心肌细胞再生而改善扩张型心肌病的心功能。展开更多
Introduction: Vascular endothelial growth factor-C (VEGF-C) is the primary lymphangiogenic factor that stimulates lymphangiogenesis by signaling via specific receptor, vascular endothelial growth factor receptor 3 (VE...Introduction: Vascular endothelial growth factor-C (VEGF-C) is the primary lymphangiogenic factor that stimulates lymphangiogenesis by signaling via specific receptor, vascular endothelial growth factor receptor 3 (VEGFR3). This study was conducted to evaluate the change in the level of VEGF-C before and after autologous bone marrow mononuclear cell transplantation for treatment of Lower limb lymphedema. Patient and methods: Forty patients with lower limb lymphedema were divided into two groups. Group I included 20 patients with chronic lower limb lymphedema who underwent autologous bone marrow mononuclear cell transplantation. Group II included 20 patients with chronic lower limb lymphedema who were exposed only to compression therapy as a control group. VEGF-C level in the diseased limbs was measured in both groups at the beginning of the study then 3 and 6 months respectively. Results: Group I included 20 patients, 8 patients were male (40%) and 12 patients were females (60%) with mean age 29.5 ± 12.15 while group II included 20, 10 patients were male (50%) and 10 patients were females (50%) with mean age 39.5 ± 11.5. In group I, the specimens were taken at 3 and 6 months after transplantation showed a marked decrease in the VEGF-C level with statistically significant p value, 0.02 and 0.001 respectively. In group II the level of VEGF-C after compression therapy alone at 3 and 6 months interval showed fluctuation with statistically non-significant p value, 0.64 and 0.55 respectively. Conclusion: VEGF-C is essential for regulation of lymphangiogenesis. The level of VEGF-C was found elevated in patients with lymphedema and decrease after autologous mononuclear bone marrow cells, however these results were statically non-significant.展开更多
文摘目的:观察自体骨髓单个核细胞冠脉内移植治疗扩张型心肌病的临床疗效。方法:扩张型心肌病16例(男性5例, 女性11例),平均年龄(45．3±10．8)岁,心功能Ⅳ级,左室射血分数(LVEF)<30％。抽取骨髓,用Ficoll密度梯度离心法分离骨髓单个核细胞,经外周动脉穿刺插管,将骨髓单个核细胞分别直接注入左、右冠脉。比较移植前后心功能的变化。结果:移植3个月后,心功能(NYHA分级)得到改善,总有效率87．5％,超声心动图检查均示左室舒张末径(mm)(72．94± 4．01 vs 63．63±2．58．P<0．001)、左室收缩末径(mm)(52．00±2．80 vs 44．38±1．78．P<0．001)减小,左室射血分数(％) (22．88±5．29vs33．81±3．33,P<0．001)、短轴缩短率(％)(12．00±2．39 vs 20．94±3．70,P<0．001)明显增加;心脏ECT 检查与术前相比,术后患者缺血及坏死心肌节段减少,(3．4±0．3vs2．1±0．4,P<0．05)(2．5±0．5 vs 1．6±0.3,P< 0．01)个。结论:自体骨髓单个核细胞移植有可能通过缺血心肌血运改善,坏死心肌区有心肌细胞再生而改善扩张型心肌病的心功能。
文摘Introduction: Vascular endothelial growth factor-C (VEGF-C) is the primary lymphangiogenic factor that stimulates lymphangiogenesis by signaling via specific receptor, vascular endothelial growth factor receptor 3 (VEGFR3). This study was conducted to evaluate the change in the level of VEGF-C before and after autologous bone marrow mononuclear cell transplantation for treatment of Lower limb lymphedema. Patient and methods: Forty patients with lower limb lymphedema were divided into two groups. Group I included 20 patients with chronic lower limb lymphedema who underwent autologous bone marrow mononuclear cell transplantation. Group II included 20 patients with chronic lower limb lymphedema who were exposed only to compression therapy as a control group. VEGF-C level in the diseased limbs was measured in both groups at the beginning of the study then 3 and 6 months respectively. Results: Group I included 20 patients, 8 patients were male (40%) and 12 patients were females (60%) with mean age 29.5 ± 12.15 while group II included 20, 10 patients were male (50%) and 10 patients were females (50%) with mean age 39.5 ± 11.5. In group I, the specimens were taken at 3 and 6 months after transplantation showed a marked decrease in the VEGF-C level with statistically significant p value, 0.02 and 0.001 respectively. In group II the level of VEGF-C after compression therapy alone at 3 and 6 months interval showed fluctuation with statistically non-significant p value, 0.64 and 0.55 respectively. Conclusion: VEGF-C is essential for regulation of lymphangiogenesis. The level of VEGF-C was found elevated in patients with lymphedema and decrease after autologous mononuclear bone marrow cells, however these results were statically non-significant.
